MX379357B - Formulación farmacéutica para usarse en el tratamiento tópico de una úlcera crónica. - Google Patents

Formulación farmacéutica para usarse en el tratamiento tópico de una úlcera crónica.

Info

Publication number
MX379357B
MX379357B MX2016006091A MX2016006091A MX379357B MX 379357 B MX379357 B MX 379357B MX 2016006091 A MX2016006091 A MX 2016006091A MX 2016006091 A MX2016006091 A MX 2016006091A MX 379357 B MX379357 B MX 379357B
Authority
MX
Mexico
Prior art keywords
ulcer
wound
application
formulation
treatment
Prior art date
Application number
MX2016006091A
Other languages
English (en)
Spanish (es)
Other versions
MX2016006091A (es
Inventor
Alvar Grönberg
Christine Dieterich
Margit Mahlapuu
Original Assignee
Pergasus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pergasus Ab filed Critical Pergasus Ab
Publication of MX2016006091A publication Critical patent/MX2016006091A/es
Publication of MX379357B publication Critical patent/MX379357B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2016006091A 2013-11-19 2014-11-19 Formulación farmacéutica para usarse en el tratamiento tópico de una úlcera crónica. MX379357B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/GB2013/053053 WO2015075406A1 (en) 2013-11-19 2013-11-19 New treatment of chronic ulcers
PCT/GB2014/053415 WO2015075441A1 (en) 2013-11-19 2014-11-19 New treatment of chronic ulcers

Publications (2)

Publication Number Publication Date
MX2016006091A MX2016006091A (es) 2016-12-09
MX379357B true MX379357B (es) 2025-03-11

Family

ID=49998562

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006091A MX379357B (es) 2013-11-19 2014-11-19 Formulación farmacéutica para usarse en el tratamiento tópico de una úlcera crónica.

Country Status (15)

Country Link
US (3) US10226508B2 (https=)
EP (1) EP3071216B1 (https=)
JP (1) JP6539268B2 (https=)
KR (1) KR102360938B1 (https=)
CN (1) CN105939726A (https=)
AU (1) AU2014351607B2 (https=)
BR (1) BR112016011166A8 (https=)
CA (1) CA2927557C (https=)
ES (1) ES2925876T3 (https=)
MX (1) MX379357B (https=)
PL (1) PL3071216T3 (https=)
RU (1) RU2707254C1 (https=)
TW (1) TWI698251B (https=)
WO (2) WO2015075406A1 (https=)
ZA (1) ZA201604110B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0808376D0 (en) 2008-05-08 2008-06-18 Bristol Myers Squibb Co Wound dressing
GB0817796D0 (en) 2008-09-29 2008-11-05 Convatec Inc wound dressing
GB201020236D0 (en) 2010-11-30 2011-01-12 Convatec Technologies Inc A composition for detecting biofilms on viable tissues
PL2648795T3 (pl) 2010-12-08 2023-05-08 Convatec Technologies Inc. System do usuwania wysięków z miejsca rany
JP5965409B2 (ja) 2010-12-08 2016-08-03 コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ 創傷滲出液を評価するための統合システム
CN103347562B (zh) 2010-12-08 2016-08-10 康沃特克科技公司 伤口分泌液系统附件
GB201115182D0 (en) 2011-09-02 2011-10-19 Trio Healthcare Ltd Skin contact material
GB2497406A (en) 2011-11-29 2013-06-12 Webtec Converting Llc Dressing with a perforated binder layer
GB201120693D0 (en) 2011-12-01 2012-01-11 Convatec Technologies Inc Wound dressing for use in vacuum therapy
JP2016507663A (ja) 2012-12-20 2016-03-10 コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ 化学修飾セルロース系繊維の加工
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
JP6738833B2 (ja) 2015-04-28 2020-08-12 コンバテック・テクノロジーズ・インコーポレイテッドＣｏｎｖａｔｅｃ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ 抗細菌性ナノファイバー
GB2543544A (en) 2015-10-21 2017-04-26 Brightwake Ltd Wound dressing
WO2017173069A1 (en) 2016-03-30 2017-10-05 Convatec Technologies Inc. Detecting microbial infections in wounds
WO2017212345A2 (en) 2016-03-30 2017-12-14 Synovo Gmbh Detecting microbial infection in wounds
GB201608099D0 (en) 2016-05-09 2016-06-22 Convatec Technologies Inc Negative pressure wound dressing
JP7071957B2 (ja) 2016-07-08 2022-05-19 コンバテック・テクノロジーズ・インコーポレイテッド 可撓性陰圧システム
BR112019000284A2 (pt) 2016-07-08 2019-04-16 Convatec Technologies Inc. aparelho de coleta de fluido
ES2912094T3 (es) 2016-07-08 2022-05-24 Convatec Technologies Inc Detección de flujo de fluidos
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
FI3638251T3 (fi) 2017-06-12 2024-04-29 Lakewood Amedex Inc Bisfosfosiinin geeliformulaatioita ja niiden käyttötapoja
US12161792B2 (en) 2017-11-16 2024-12-10 Convatec Limited Fluid collection apparatus
SG11202103180QA (en) 2018-10-17 2021-05-28 Lakewood Amedex Inc Methods and compositions for treating oral mucositis
EP4295869B1 (en) 2019-06-03 2026-01-28 Convatec Limited Devices to disrupt and contain pathogens
US11771819B2 (en) 2019-12-27 2023-10-03 Convatec Limited Low profile filter devices suitable for use in negative pressure wound therapy systems
US11331221B2 (en) 2019-12-27 2022-05-17 Convatec Limited Negative pressure wound dressing

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
EP0935965A4 (en) 1996-04-23 2002-01-23 Toray Industries SUBSTANCE AGAINST PYLORI
EP0928206B1 (en) * 1996-07-11 2004-04-14 Coloplast A/S A hydrocolloid wound gel
US6861067B2 (en) * 1998-09-17 2005-03-01 Sherwood Services Ag Hydrogel wound dressing and the method of making and using the same
US6835713B2 (en) 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
EP1358888A1 (en) 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US7262179B2 (en) * 2003-05-28 2007-08-28 Bristol-Myers Squibb Company Wound care compositions
EP1621205A1 (en) * 2004-07-28 2006-02-01 OctoPlus Technologies B.V. Antimicrobial peptides derived from CAP18
ZA200600686B (en) * 2006-01-24 2006-04-26 Jacobus F Mouton A wound dressing
WO2008088922A2 (en) * 2007-01-19 2008-07-24 Genentech, Inc. Prevention of hydrogel viscosity loss
CN101720237A (zh) * 2007-06-25 2010-06-02 利波佩普蒂德有限公司 新型医用产品
CA2734577A1 (en) * 2007-08-16 2009-02-26 Carnegie Mellon University Inflammation-regulating compositions and methods
US9101586B2 (en) 2007-12-28 2015-08-11 Augustine Bader Topical application and formulation of erythropoietin for skin wound healing
AU2010316006B2 (en) 2009-11-03 2013-09-26 Lipidor Ab Composition for promoting wound healing
CA2810844C (en) * 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
US9693936B2 (en) * 2012-03-07 2017-07-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Dispersions in oil of Dead Sea nano sized material preparation and uses therof
WO2013163423A1 (en) * 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers

Also Published As

Publication number Publication date
EP3071216B1 (en) 2022-08-03
JP2016537373A (ja) 2016-12-01
EP3071216A1 (en) 2016-09-28
CA2927557C (en) 2023-05-02
BR112016011166A2 (https=) 2017-08-08
MX2016006091A (es) 2016-12-09
AU2014351607B2 (en) 2020-03-05
RU2016124234A (ru) 2017-12-25
KR20160088914A (ko) 2016-07-26
ZA201604110B (en) 2020-11-25
US20200384077A1 (en) 2020-12-10
AU2014351607A1 (en) 2016-06-23
TWI698251B (zh) 2020-07-11
KR102360938B1 (ko) 2022-02-09
TW201521760A (zh) 2015-06-16
CA2927557A1 (en) 2015-05-28
US10226508B2 (en) 2019-03-12
US10709760B2 (en) 2020-07-14
US20190255147A1 (en) 2019-08-22
PL3071216T3 (pl) 2022-11-21
BR112016011166A8 (pt) 2022-06-28
WO2015075406A1 (en) 2015-05-28
ES2925876T3 (es) 2022-10-20
RU2707254C1 (ru) 2019-11-25
CN105939726A (zh) 2016-09-14
JP6539268B2 (ja) 2019-07-03
US20160271217A1 (en) 2016-09-22
US11191810B2 (en) 2021-12-07
WO2015075441A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
MX379357B (es) Formulación farmacéutica para usarse en el tratamiento tópico de una úlcera crónica.
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
MX382195B (es) Sistema terapeutico transdermico que contiene asenapina
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
BR112014000775A2 (pt) curativo de ferimento e método de tratamento
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2022000270A (es) Dispositivo para el suministro de una composicion para el cuidado de la piel.
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
MX366502B (es) Composiciones y métodos para tratar heridas superficiales.
SA519400913B1 (ar) تركيبة موضعية لتعزيز إلتئام الجروح
ITMI20120370A1 (it) Miscela antimicrobica e rivestimento per supportare la guarigione di ferite, che ha un effetto antimicrobico.
MX388251B (es) Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
MY179605A (en) Use of benzimidazole-proline derivatives
MX376183B (es) Composiciones para el tratamiento de rosacea.
EA201591055A1 (ru) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
WO2019099860A3 (en) Wound treatment containing collagen and a gelatin-reducing agent, and method for promoting wound healing
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
MX374354B (es) Método de curación de heridas.
EA201790220A1 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
WO2015069656A8 (en) Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients
MX350080B (es) Composicion anti-inflamatoria para coadyuvar y favorecer el proceso de cicatrizacion de lesiones ulcerosas cronicas.
WO2015057964A3 (en) Modulation of mrtf-a activity in pathologic fibrosis and wound healing
UA79462U (ru) Способ местного лечения венозных трофических язв
MX2016002139A (es) Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo.
MX2012002783A (es) Composicion farmaceutica que comprende un extracto hexano-acetato de etilo de ageratina pichinchensis y su uso para el tratamiento y cura de ulceras venosas cronicas.